Anthem Biosciences Limited Share Price & Stock Analysis

Anthem Biosciences Limited (NSE: ANTHEM, BSE: 544449) is a Bengaluru, Karnataka-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹53,926 Cr, it ranks #196 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 11 in Pharmaceutical CDMO and CRO Services. At ₹933.60 (as of 16 Nov 2026), the share price is 5.6% below its 52-week high of ₹989.10 and 61.2% above its 52-week low of ₹579.15. The share price is up 34.5% over one year and up 7.1% over three months.

Key Metrics

Current Price₹933.60
Market Cap₹53,926 Cr
NSE SymbolANTHEM
BSE Code544449
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services
Sub-IndustryLife Sciences Tools and Services > Pharmaceutical CDMO and CRO Services
P/E Ratio90.1
Return on Equity19.45%
Return on Assets14.20%
52-Week Range₹579.15 – ₹989.10
1-Year Price Change+34.5%
3-Month Price Change+7.1%
Beta (1Y)0.41
Dividend Yield0.21%
HeadquartersBengaluru, Karnataka
Websiteanthembio.com

Latest Quarterly Results — Q2 FY27

Revenue₹594 Cr
Net Profit₹211 Cr
Net Margin35.6%
EPS (Basic)₹3.75
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Anthem Biosciences Limited Quarterly Revenue and Profit Trend

Anthem Biosciences Limited reported revenue of ₹594 Cr in Q2 FY27, up 8.0% from ₹550 Cr in Q2 FY26 and up 42.0% from ₹418 Cr in Q1 FY27. It posted a net profit of ₹211 Cr for the quarter, against a net profit of ₹173 Cr in Q2 FY26 (up 21.9%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹418 Cr (Q1 FY27) to ₹611 Cr (Q4 FY26). The company was profitable in each of these 6 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹594 Cr₹211 Cr35.6%
Q1 FY27₹418 Cr₹120 Cr28.7%
Q4 FY26₹611 Cr₹190 Cr31.1%
Q3 FY26₹423 Cr₹93 Cr21.9%
Q2 FY26₹550 Cr₹173 Cr31.5%
Q1 FY26₹540 Cr₹136 Cr25.1%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 71.40% of Anthem Biosciences Limited's shares as of Sept 2026, against 74.69% in Sept 2025 (−3.29 percentage points). Delivery averaged 50.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Anthem Biosciences Limited

Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.

Products and Services

1. Contract Research Development & Manufacturing Services (CRDMO)-This segment offers a range of contract research development and manufacturing services for molecules used for clinical trials. 2. Speciality Ingredients-This segment manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. 3. Segment Adjustment-NA 4. R & D Services-This segment engages in research and development services.

Business Segments

1. Contract Research Development & Manufacturing Services (CRDMO)-83.4% 2. Speciality Ingredients-16.6%

Anthem Biosciences Limited vs Peers — Pharmaceutical CDMO and CRO Services

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Divis Laboratories Limited₹3,01,758 Cr118.416.19%₹3,676 Cr+71.9%
Anthem Biosciences Limited₹53,926 Cr90.119.45%₹594 Cr+34.5%
Sai Life Sciences Limited₹40,755 Cr116.115.13%₹659 Cr+120.3%
Onesource Specialty Pharma Limited₹18,138 Crn/m-1.26%₹516 Cr-9.4%
Cohance Lifesciences Ltd₹17,756 Cr100.65.11%₹477 Cr-35.2%
Syngene International Ltd.₹17,630 Cr56.96.62%₹833 Cr-27.9%
Jubilant Pharmova Ltd₹15,556 Cr39.15.96%₹2,370 Cr-14.5%
Concord Biotech Ltd₹12,495 Cr24.213.54%₹309 Cr-14.8%
Blue Jet Healthcare Ltd₹10,140 Cr3819.88%₹376 Cr-9.8%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Anthem Biosciences Limited?

Anthem Biosciences Limited is trading at ₹933.60, with a market capitalisation of ₹53,926 Cr.

Which sector does Anthem Biosciences Limited belong to?

Anthem Biosciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).

What are the key financial ratios of Anthem Biosciences Limited?

Anthem Biosciences Limited has a P/E of 90.1 and a return on equity of 19.45%.

What is the stock symbol of Anthem Biosciences Limited?

Anthem Biosciences Limited is listed on the NSE under the symbol ANTHEM and on the BSE under the scrip code 544449.

How has Anthem Biosciences Limited's share price moved over the past year?

Anthem Biosciences Limited's share price is up 34.5% over one year and up 7.1% over three months. Its 52-week range is ₹579.15 to ₹989.10.

What were Anthem Biosciences Limited's latest quarterly results?

In Q2 FY27, Anthem Biosciences Limited reported revenue of ₹594 Cr and net profit of ₹211 Cr, with basic EPS of ₹3.75 (consolidated, parsed from the company's exchange filing).

How have Anthem Biosciences Limited's revenue and profit changed over the past year?

Anthem Biosciences Limited reported revenue of ₹594 Cr in Q2 FY27, up 8.0% from ₹550 Cr in Q2 FY26 and up 42.0% from ₹418 Cr in Q1 FY27.

What is the promoter holding in Anthem Biosciences Limited?

Promoters held 71.40% of Anthem Biosciences Limited's shares as of Sept 2026, against 74.69% in Sept 2025 (−3.29 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.